Sativex Spray Provided Meaningful Spasticity Relief for MS Patients Who Failed Other Treatments | Research

The takeaway

THC/CBD oromucosal spray (Sativex) reduced spasticity by 30% or more in about three-quarters of initial responders among MS patients resistant to other anti-spasticity medications, with continued benefit for at least a year without dose escalation.

Read this if you have MS spasticity that has not responded to standard medications.

75% of initial responders achieved 30%+ spasticity reduction with sustained benefit

What the researchers found

The review summarized the clinical evidence for Sativex in MS spasticity. Up to 80% of MS patients experience spasticity during their disease course, and about one-third have moderate or severe symptoms despite oral anti-spasticity drugs. Sativex was recently approved in EU countries for treatment-resistant MS spasticity.

In clinical trials, Sativex provided initial relief within 4 weeks in about half of treatment-resistant patients. Among these initial responders, three-quarters achieved clinically significant improvement (30%+ reduction). In real-world practice, the mean daily dose was about 5 sprays, over 80% reported no adverse events, and follow-up studies showed continued benefit for at least 1 year without dose increases.

Why it matters

The "trial and respond" approach (4-week initial trial, continue only in responders) is clinically practical and maximizes benefit-to-risk ratio. The absence of dose escalation over a year addresses the key tolerance concern. Sativex fills a genuine gap for the one-third of MS patients with inadequately treated spasticity.

The numbers in context

80% of MS patients experience spasticity. ~33% have moderate-severe despite treatment. Initial response in ~50% within 4 weeks. 30%+ improvement in 75% of responders. Mean daily dose: ~5 sprays. >80% no AEs. Benefit maintained 1+ year without dose increase.

How the study worked

Expert review of clinical trial data, real-world practice data, and safety registry data for Sativex in MS spasticity. Covered the 4-week trial period approach for identifying responders.

What this study cannot tell us

Expert review perspective rather than systematic review. Real-world data may reflect selection bias (patients who benefit continue, others stop). The 4-week trial period may miss slow responders. Long-term data beyond 1 year was limited at the time.

How to read the evidence

Expert review synthesizing clinical trial and real-world data; moderate evidence for efficacy and long-term safety.

When this study was published

Published in 2013. Sativex has gained further regulatory approvals and accumulated more long-term data since.

The bigger picture

Sativex represents the first approved cannabinoid medication specifically for MS spasticity in Europe. Its approval validated the concept that standardized cannabinoid preparations can fill legitimate medical needs while managing psychoactive risks through controlled dosing and the CBD component.

Questions still open

Can the responder/non-responder pattern be predicted in advance? Would Sativex benefit MS patients earlier in their disease? How does Sativex compare to higher-dose oral anti-spasticity medications?

Common questions

How quickly does Sativex work for MS spasticity?

Clinical trials showed that about half of treatment-resistant MS patients experienced initial relief within 4 weeks. This 4-week trial period is used clinically to identify responders. Among those who respond initially, three-quarters achieve meaningful improvement (30% or greater reduction in spasticity).

Does Sativex lose effectiveness over time?

Follow-up data showed continued benefit for at least one year without patients needing to increase their dose. This absence of tolerance development is important because tolerance is a common concern with cannabinoid medications. The mean daily dose remained stable at about 5 sprays.

Read the original research

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Expert review of neurotherapeutics, 13(12 Suppl), 49-54

View on PubMed ↗Publisher’s paper ↗

Citation

Pozzilli, Carlo. (2013). Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.. Expert review of neurotherapeutics, 13(12 Suppl), 49-54. https://doi.org/10.1586/14737175.2013.865877